Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | CNR1 | P21554 | 12/20 | 0.41 |
| ▸ | CNR2 | P34972 | 12/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11907068 | 0.89 | CNR1 (0.46) | MEN1HPGDKMT2AMAPTCNR1 | |
| SCHEMBL2746572 | 0.87 | CNR1 (0.49) | MEN1HPGDKMT2AMAPTCNR1 | |
| SCHEMBL2746576 | 0.84 | MAPT (0.50) | MEN1HPGDKMT2AMAPTCNR1 | |
| SCHEMBL11907675 | 0.84 | CNR2 (0.48) | CNR1CNR2 | |
| SCHEMBL11906690 | 0.83 | CNR2 (0.61) | CNR1CNR2 | |
| SCHEMBL11907258 | 0.83 | CNR2 (0.61) | CNR1CNR2 | |
| SCHEMBL11907303 | 0.82 | CNR2 (0.61) | CNR1CNR2 | |
| SCHEMBL11907051 | 0.82 | CNR2 (0.61) | CNR1CNR2 | |
| SCHEMBL11906095 | 0.82 | CNR2 (0.60) | CNR1CNR2 | |
| SCHEMBL11906660 | 0.80 | CNR2 (0.50) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | CNR2, CNR1, HRH4 | MEN1 4298/4885HPGD 1235/4885KMT2A 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.